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Background. New biomarkers are necessary to improve detection of the risk of infection in heart transplantation. We 
performed a multicenter study to evaluate humoral immunity profiles that could better enable us to identify heart 
recipients at risk of severe infections. 
Methods. We prospectively analyzed 170 adult heart recipients at 8 centers in Spain. Study points were before 
transplantation and 7 and 30 days after transplantation. Immune parameters included IgG, IgM, IgA and complement 
factors C3 and C4, and titers of specific antibody to pneumococcal polysaccharide antigens (anti-PPS) and to 
cytomegalovirus (CMV). To evaluate potential immunologic mechanisms leading to IgG hypogammaglobulinemia, 
before heart transplantation we assessed serum B-cell activating factor (BAFF) levels using enzyme-linked 
immunoassay. The clinical follow-up period lasted 6 months. Clinical outcome was need for intravenous anti-
microbials for therapy of infection. 
Results. During follow-up, 53 patients (31.2%) developed at least 1 severe infection. We confirmed that IgG 
hypogammaglobulinemia at Day 7 (defined as IgG <600 mg/dl) is a risk factor for infection in general, bacterial 
infections in particular, and CMV disease. At Day 7 after transplantation, the combination of IgG <600 mg/dl + C3 
<80 mg/dl was more strongly associated with the outcome (adjusted odds ratio 7.40; 95% confidence interval 1.48 to 
37.03; p = 0.014). We found that quantification of anti-CMV antibody titers and lower anti-PPS antibody 
concentrations were independent predictors of CMV disease and bacterial infections, respectively. Higher pre-
transplant BAFF levels were a risk factor of acute cellular rejection. 
Conclusion. Early immunologic monitoring of humoral immunity profiles proved useful for the identification of heart 
recipients who are at risk of severe infection. 
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Infections continue to be a barrier to long-term survival in heart recipients. According to the 2014 
report of the Registry of the International Society for Heart and Lung Transplantation, infection is the 
leading cause of death between 1 month and 1 year after transplantation.
1
 New early biomarkers are 
needed to improve assessment of the risk of developing infection after heart transplantation.
2
  
 
Immunoglobulin G (IgG) hypogammaglobulinemia has been evaluated extensively in heart 
transplantation. Previous studies have analyzed the role of monitoring IgG concentrations in various 
immunosuppressive settings.
3–6
 A recently published meta-analysis suggested that IgG 
hypogammaglobulinemia is a risk factor for infection in solid-organ recipients.
7
 However, previous 
studies are limited by the fact that data were gathered from a single institution. Multicenter studies are 
necessary to validate biomarkers for use in clinical practice.  
 
In this study we present the results of a multicenter, prospective, observational study of humoral 
immunity biomarkers in adult heart recipients. The specific aims of this multicenter study were as 
follows: (1) to confirm whether IgG hypogammaglobulinemia is an independent risk factor of severe 
infection; (2) to identify humoral immunity profiles that could better enable us to identify the risk of 
infection; (3) to evaluate the reproducibility of IgG and complement factor 3 (C3) testing results in 
different centers; and (4) to evaluate potential immune factors of hypogammaglobulinemia before heart 
transplantation. 
Methods  
Study design  
We prospectively evaluated 170 adult patients undergoing heart transplantation in 8 geographically 
dispersed teaching hospitals in Spain. The centers were distributed as follows: Madrid (Hospital General 
Universitario Gregorio Marañon [coordinating center, n = 59], Hospital Universitario Doce de Octubre [n 
= 27], Hospital Universitario Puerta de Hierro [n = 8]); La Coruña (Complexo Hospitalario Universitario 
A Coruña [n = 26]); Navarra (Clinica Universitaria de Navarra [n = 19]); Valladolid (Hospital Clínico 
Universitario [n = 9]); Valencia (Hospital Universitario La Fe [n = 20]); and Barcelona (Hospital de la 
Santa Creu i Sant Pau [n = 2]). Data were collected later at some centers than at others. Twenty-five 
patients from the coordinating center overlapped with the population studied in a previous publication.
8
  
 
The clinical characteristics of the patients are presented in Supplementary Table S1 (available online 
www.jhltonline.org). Induction therapy was taken by 147 patients (86.5%; anti-CD25 monoclonal 
antibodies, n = 146; anti-thymocyte globulin, n = 1). The frequency of induction therapy was similar 
between institutions and ranged from 86% to 100%. With respect to maintenance immunosuppression 
therapy, 54 patients (31.8%) received cyclosporine and 107 received tacrolimus (62.9%). Differences 
were observed between the centers. The frequency of administration of cyclosporine varied from 15% to 
100%, and that of tacrolimus from 25 % to 100%. Mycophenolate mofetil was taken by 164 patients 
(96.5%), with few differences in frequency (range 86% to 100%). During the 6 months of follow-up, 
none of the patients used proliferation signal inhibitors (everolimus or rapamycin).  
 
Anti-microbial prophylaxis included peri-transplant cephalosporins in 133 patients (78.2%), 
quinolones during the first month in 75 (44.1%), and trimethoprim–sulfamethoxazole during the 6-month 
follow-up period in 123 patients (72.4%). As for anti-cytomegalovirus (anti-CMV) prophylaxis, 69 
patients (40.6%) received valganciclovir, 30 (17.6%) received ganciclovir, and 47 (27.6%) did not receive 
CMV prophylaxis. Differences were detected between the centers. The frequency of administration of 
valganciclovir varied from 4.2% to 100%, and that of ganciclovir from 0% to 100%. As for anti-fungal 
prophylaxis, nystatin was indicated in 147 patients (86.5%). None of the patients received intravenous 
immunoglobulin (IVIg) before the immunologic tests performed at Day 7 after transplantation. One 
patient received IVIg after diagnosis of thrombocytopenic purpura at Day 14 after transplantation. No 
patients received IVIg before development of a severe infection.  
The follow-up period was the 6 months after transplantation. Severe infections were defined according 
to the definitions of the U.S. Centers for Disease Control and Prevention. The only infections included 
were severe infections, that is, those requiring intravenous anti-microbial therapy in hospital. Superficial 
surgical-site infections and catheter-associated infections were not included. CMV disease was defined as 
positive results in CMV antigenemia or polymerase chain reaction (PCR) assay and clinical symptoms. 
 
Clinical and epidemiologic data on all patients enrolled in the study were collected by local 
investigators during the follow-up period. Rejection episodes were diagnosed based on endomyo-cardial 
biopsy findings. We included only treated rejection episodes in the analysis.  
Immunologic studies  
Immunologic tests were performed in serum samples obtained at inclusion on the waiting list and at 
Days 7 and 30after transplantation. Levels of immunoglobulins (IgG, IgA, IgM) and complement factors 
(C3 and C4) were determined using nephelometry (Beckman-Coulter-Izasa, Brea, CA). Variations in the 
kinetics and values of selected immunologic parameters (IgG and C3) among patients in heart transplant 
units at the various institutions were observed to assess the reproducibility of biomarkers. 
 
The evaluation of specific risk factors of CMV disease included assessment of IgG anti-CMV 
antibodies using a commercial enzyme-linked immunoassay (ELISA) kit. Microtitration plates were 
coated with inactivated CMV antigens derived from human fibroblasts infected with CMV (Enzygnost 
Anti-CMV IgG; Siemens Healthcare Diagnostics, Marburg, Germany). 
 
A substudy was also performed to identify humoral immunity–specific risk factors for severe bacterial 
infection. The specific IgG response to polysaccharide antigens was evaluated using a multivalent 
pneumococcal polysaccharide ELISA kit containing 23 serotypes of Pneumococcus pneumoniae (Binding 
Site; Birmingham, UK). This is an accepted surrogate biomarker for the evaluation of immune 
competence against polysaccharide antigens in bacterial infections. 
 
To evaluate potential immunologic mechanisms leading to IgG hypogammaglobulinemia before heart 
transplantation we assessed serum B-cell activating factor (BAFF) levels in frozen samples. BAFF is a 
cytokine that regulates survival and selection of peripheral B-cells. Serum BAFF concentrations were 
assessed using a commercial ELISA test (HumanBAFF/BLyS/TNFSF13B Quantikine Test; R&D 
Systems, Inc., Minneapolis, MN).  
Statistical analysis 
Markers were defined according to established cut-off definitions when available (reference ranges: 
IgG, 600 to1,600 mg/dl; C3, 80 to 160 mg/dl; C4, 20 to 40 mg/dl), and receiver-operating characteristic 
(ROC) curve analysis was used to identify the best cut-off points when normal ranges were not available. 
 
We analyzed patient-related variables (demographic, pre-operative, intra-operative and post-
transplant) and 7 immunologic variables. Independent risk factors for severe infection in general and for 
specific infections (CMV disease or bacterial infection) were assessed using multivariable logistic 
regression. The odds ratio (OR) was used as a measure of relative risk. p < 0.05 was considered 
significant. A step wise approach was used to determine which of the factors or variables studied were 
most strongly associated with severe infections. Variables with significant colinearity (correlation 
coefficients > 80%) were dropped from the analysis. Regardless of statistical significance, the variable 
“participating center” was left in models to account for potential unmeasured differences between the 
institutions in the risk of developing severe infections. A Kaplan–Meier analysis was used to calculate the 
cumulative probability of severe infections after transplantation according to the levels of immunologic 
biomarkers performed at the earliest time-point after transplantation (i.e., 7 days after transplantation). An 
immunologic score was then created. ORs were used to determine the number of points assigned to each 
of the earliest immunologic individual risk factors with the highest specificity (> 80%) and the sum was 
the score.  
Assessment of reproducibility  
Seven participating centers submitted serum samples to the coordinating center in Madrid to be 
analyzed for measurement of the selected biomarkers. Each institution received instructions on the 
standard procedures for sample collection, storage and shipment. All samples were aliquoted into batches 
of 500 μl. Samples were stored frozen at –30ºC until being used in the study. Four centers participated in 
the reproducibility study and tested their serum samples at their own laboratories. Data from these sites 
were then sent to the coordinating center. The goal of this study was to assess agreement between 
laboratories to evaluate the reproducibility of IgG and C3 testing. The correlation between biomarker 
levels tested at the coordinating and collaborating centers was assessed using Pearson’s correlation test. 
 
Analyses were performed using SPSS Statistics version 22 (IBM SPSS, Armonk, NY). 
Ethics 
The procedures followed in this study were in accordance with the ethical standards of our hospital 
ethics committee and with the 1975 Declaration of Helsinki. Before initiation of this study, institutional 
review board approval was obtained from the ethics committee at Gregorio Marañon Hospital (Projects 
FIS 050839, FIS 081430 and FIS 1101323). Local ethics committee approval was then obtained from all 
collaborating centers. Informed consent was obtained before the studies were performed. 
Results 
Kinetics of biomarkers  
The rates of immunologic abnormalities in the cohort of heart recipients are presented in 
Supplementary Table S2 (available at www.jhlt.org). A significant decrease in IgG concentration was 
observed up to 1 month after transplantation. We demonstrated that the kinetics of biomarkers was similar 
in all participating centers (Figure 1). The complete list of centers is shown in Figure S1 (see 
Supplementary Material online). The kinetics of C3 differed. A significant decrease was observed at 7 
days after transplantation. However, at 1 month, a recovery was observed at all centers compared with 
pre-transplant values (Figure 1, and Supplementary Figure S1, available at www. jhlt.org). As for specific 
antibodies, IgG anti-CMV and anti-pneumococcal polysaccharide antibody titers decreased significantly 
up to 1 month after transplantation (Figure 2). 
 
 
 
 
 
  
 
 
 
Figure 1 Kinetics of serum IgG and C3 in 3 heart transplant centers. 
 
 
 
Figure 2 Kinetics of specific anti-CMVand anti-PPS antibodies. Levels in infected and non-infected patients. 
  
Clinical risk factors for severe infection  
During the study period, 53 patients (31.2%) developed at least 1 episode of severe infection after 
transplantation. Mean time to the first infection was 65 days (median 45 days, interval 2 to 180 days). 
Most severe infections (77%) occurred within the first 3 months after transplantation. The distribution of 
microorganisms detected in the first infectious episode is presented in Supplementary Table S3 (available 
at www.jhlt.org). Stay at a particular institution was not significantly associated with an increased risk of 
severe infection (Table1).  
Table 1 Clinical and Immunologic Risk Factors for Development of Severe Infection  
Variable Sn Sp Odds ratiob 95% CI p-value 
      
Participating center  — — 0.91 0.79 to1.04 0.17 
Pre-transplantation risk factors       
Age > 50 yearsa 87.5 29.7 3.30 1.19 to 9.18 0.022c 
Gender: male vs female — — 1.57 0.71 to3.44 0.26 
Pre-HT diabetes mellitus 38.8 78 2.21 0.95 to 5.13 0.065 
Pre-HT mechanical ventilation — — 1.13 0.44 to 2.90 0.79 
Pre-HT infections — — 0.87 0.26 to 2.81 0.82 
Pre-HT renal failure (creatinine > 2.5 mg/dl)  — — 1.27 0.43 to 3.79 0.66 
Positive Mantoux result — — 0.99 0.458 to 2.184 0.98 
Pre transplant hypoalbuminemia (< 3.4 g/dl) — — 1.72 0.61 to 4.83 0.30 
Donor risk factors      
Donor gender: male vs female  — — 0.99 0.47 to 2.06 0.97 
Donor age 450 yearsa  — — 0.67 0.17 to 2.70 0.57 
Time in intensive care unit: donor > 5 daysa  — — 1.63 0.70 to 3.78 0.26 
Transplantation risk factors      
Retransplantation — — 1.06 0.09 to 11.97 0.96 
Urgent transplantation — — 1.53 0.71 to 3.31 0.28 
Discordant CMV receptor negative/donor positive 12 96 3.45 0.92 to 12.85 0.07 
Ventricular assist device — — 1.44 0.63 to 3.27 0.38 
Ischemia time > 220 minutesa  — — 1.47 0.69 to 3.09 0.31 
Extracorporeal circulation time > 127 minutesa  61 55 2.01 0.94 to 4.29 0.07 
Intubation time >14 hoursa  69 64 3.87 1.77 to 8.48 0.0007c 
Time inintensive care unit > 6 daysa  67 63 3.55 1.64 to 7.67 0.0013c 
Induction: basiliximab vs daclizumab  — — 0.74 0.30 to 1.81 0.51 
Induction: methylprednisolone  — — 0.84 0.36 to 1.96 0.68 
Maintenance: cyclosporine 74.5 56 0.42 0.19 to 0.93 0.032c 
Maintenance: tacrolimus  — — 1.76 0.84 to 3.71 0.13 
Use of anti-CMV prophylaxis (yes vs no) — — 1.44 0.58 to 3.43 0.44 
Ganciclovir vs valganciclovir  — — 2.52 0.73 to 8.69 0.14 
Post-HT allograft failure  — — 0.87 0.38 to 1.98 0.74 
Acute cellular rejection  — — 1.09 0.46 to 2.56 0.84 
Immunologic risk factors       
Pre-HT IgG hypogammaglobulinemia 22 90 2.66 1.06 to 6.63 0.036c 
Pre-HT C3 < 126 mg/dla  60 60 2.22 1.06 to 4.62 0.032c 
Day 7 IgG hypogammaglobulinemia  59 65 2.71 1.11 to 6.62 0.028c 
Day 7 C3 hypocomplementemia (< 80 mg/dl) 39 89 5.53 1.84 to 16.54 0.0023c 
Day 7 C4 hypocomplementemia (< 20 mg/dl) 58 64 1.98 1.03 to 5.05 0.045c 
Day 30 IgG < 450 mg/dla  23 91 3.24 1.14 to 9.19 0.027c 
Day 30 IgM < 50 mg/dla  38 82 2.62 1.08 to 6.32 0.033c 
Day 30 C3 hypocomplementemia (< 90 mg/dla)  19 93 3.14 1.01 to 9.73 0.047c 
Day 7 IgG < 600 mg/dl and C3 < 80 mg/dl 30 93 5.52 1.57 to 19.38 0.007c 
      
 
C3, complement factor 3; CI, confidence interval; HT, heart transplantation; IgG, immunoglobulin G; Sn, sensitivity; Sp, specificity.  
a Cut-off was established by receiver-operating characteristic analysis. 
b Bivariate analysis after adjustment for participating center. 
c Significant risk factors for development of severe infection. 
 
 
  
The risk factors for development of severe infection are presented in Table 1. Patients > 50 years of 
age were at higher risk of severe infection. Intubation time and time in the intensive care unit after 
transplantation were also significant clinical risk factors for infection. There was a trend toward increased 
risk of infection among patients who had diabetes, CMV-negative serostatus in the case of patients who 
had received a transplant from a CMV-positive donor, and in patients with a longer extracorporeal 
circulation time. As for the association between medication and increased risk of developing severe 
infection, treatment with tacrolimus tended to be a risk factor. Pre-transplant concentrations of total 
proteins and albumin were similar in both groups (infected vs uninfected patients; see Supplementary 
Table S1). Pre-transplant hypoalbuminemia, infection before transplant, previous mechanical ventilation 
and high-urgency waiting list status were not associated with risk of infection (Table1).  
 
We analyzed the impact of anti-microbial prophylaxis on the rate of severe infections in the early 
post-operative period (14 days after transplantation, n = 14). We found no association between 
cephalosporins and development of early infections (OR = 0.69, 95% confidence interval [CI] 0.18 to 
2.67, p = 0.59). When we evaluated the relationship between therapy with quinolones during the first 
month and the rate of early infection, again, this variable was not significantly associated with early 
infection (OR = 2.28, 95% CI 0.55 to 9.49, p = 0.26).  
Immunologic risk factors of severe infection  
An immunologic study was performed at inclusion on the waiting list. Patients with IgG 
hypogammaglobulinemia (defined as IgG < 600 mg/dl) and patients with lower C3 levels were at higher 
risk of infection. One week after transplantation, IgG hypogammaglobulinemia, C3 hypocomplementemia 
(defined as C3 < 80 mg/dl) and C4 hypocomplementemia (defined as C4 < 20 mg/dl) were significant 
risk factors for severe infection (Table 1). At Day 30 after transplantation, a lower IgG cut-off (< 450 
mg/dl) established by ROC curve analysis was associated with risk of infection, as were lower IgM and 
C3 levels (Table 1).  
Multivariate analyses  
Table 2 shows the results of the multivariate analysis for the entire cohort with respect to the 
immunologic factors that were independently associated with increased risk of severe infection after 
adjustment for age > 50 years, number of days in the ICU, use of cyclosporine and participating center. 
The variable intubation time was not included in the final model because it was significantly associated 
with time in the ICU (2-tailed correlation, p < 0.0001). IgG hypogammaglobulinemia at Days 7 and 30 
and C3 hypocomplementemia at Day 7 continued to be significant risk factors.  
 
Interestingly, the combination of both factors at Day 7 was more strongly associated with the risk of 
severe infection (Table 2).  
 
Figure 3 shows the Kaplan–Meier survival curves for length of time after immunologic monitoring at 
Day 7 until occurrence of severe infection for heart recipients, according to levels of the independent 
immunologic predictors.  
 
  
Table 2 Multivariate Logistic Regression Analysis of Immunologic Risk Factors for Development of Severe Infection 
Variable  Odds ratiob 95% CI p-value 
    
Pre-HT IgG hypogammaglobulinemia (< 600 mg/dl)  1.88 0.54 to 6.14 0.325 
Pre-HT C3 < 126 mg/dla  1.56 0.61 to 4.01 0.351 
Day 7 IgG hypogammaglobulinemia (< 600 mg/dl)  4.39 1.32 to 14.61 0.015 
Day 7 C3 hypocomplementemia (< 80 mg/dl)  5.81 1.28 to 26.40 0.022 
Day 7 C4 hypocomplementemia (< 20 mg/dl)  1.09 0.31 to 3.90 0.88 
Day 30 IgG hypogammaglobulinemia (< 450 mg/dla)  3.99 1.09 to 14.56 0.036 
Day 30 IgM hypogammaglobulinemia (< 50 mg/dl)  2.68 0.92 to 7.83 0.071 
Day 30 C3 hypocomplementemia (< 90 mg/dla)  1.66 0.43 to 6.41 0.46 
Profile Day7: IgG < 600 mg/dl and C3 < 80 mg/dl  7.40 1.48 to 37.03 0.014 
Immunologic score ≥ 4  11.0 2.68 to 45.07 0.0009 
    
 
C3, complement factor 3;CI, confidence interval; HT, heart transplantation; IgG, immunoglobulin G. 
a Cut-off was established by receiver-operating characteristic analysis.  
b After adjustment for treatment with cyclosporine, age > 50 years, time in the intensive care unit > 6 days, and participating center. 
Odds ratios were used to determine the number of points assigned to each of the 4 individual risk factors of the immunologic score 
(pre-transplant IgG < 600 mg/dl = 2 points, discordant CMV receptor negative/donor positive = 3 points, Day 7 IgG < 600 mg/dl = 
2 points and Day 7 C3 < 80 mg/dl = 5 points). 
 
 
 
Figure 3 Kaplan–Meier curves showing the cumulative risk for development of severe infection during follow-up according to 
levels of distinct humoral immunity biomarkers performed at 7 days after transplantation. IgG: serum IgG(mg/dl); C3: serum 
complement C3 (mg/dl); C4: serum complement C4 (mg/dl). 
  
Immunologic score  
An immunologic score was then created. Odds ratios were used to determine the number of points 
assigned to each of the earliest individual risk factors (assessed before transplantation and at Day 7) with 
the highest specificity (> 80%; pre-transplant IgG < 600 mg/dl = 2 points, discordant CMV receptor 
negative/donor positive = 3 points, Day 7 IgG < 600 mg/dl = 2 points, Day 7 C3 < 80 mg/dl = 5 points). 
ROC analysis showed maximum efficiency at a score of ≥ 4 to be a cut-off for severe infection. After 
adjustment for clinical risk factors, an immunologic score of ≥ 4 indicated an 11-fold greater risk for 
developing severe infection during the first 6 months after transplantation (Table2). The score effect with 
the risk of severe infection was as follows: severe infection developed in 15.6 % of patients with 0 point; 
32.2 % of patients with 1 to 3 points; and 61.1 % of patients with ≥ 4 points (2-sided chi-square test, p = 
0.003).  
Immunologic risk factors for specific infections  
For this analysis, we considered the prevalence of the first specific infection detected. A total of 33 
patients had severe bacterial infections. Univariate regression analysis revealed the immunologic risk 
factors for development of severe bacterial infections to be IgG hypogammaglobulinemia (< 600 mg/dl), 
C3 and C4 hypocomplementemia at Day 7 and IgG levels < 500 mg/dl and C3 and C4 
hypocomplementemia at 1 month (see Table S4 in Supplementary Material online). The independent risk 
factors for severe bacterial infection after adjustment for clinical risk factors were IgG 
hypogammaglobulinemia and C3 hypocomplementemia at Day 7 and IgG levels < 500 mg/dl at 1 month 
(Table 3). 
Table 3 Multivariate Logistic Regression Analysis of Immunologic Risk Factors for Development of Severe Bacterial Infections  
Variable  Odds ratiob 95% CI p-value 
    
Day 7 IgG hypogammaglobulinemia (< 600 mg/dl)  3.36 1.13 to 9.97 0.0292 
Day 7 C3 hypocomplementemia (< 80 mg/dl)  3.59 1.05 to 12.24 0.041 
Day 30 IgG hypogammaglobulinemia (< 500 mg/dla)  1.73 0.55 to 5.42 0.35 
Day 30 C3 hypocomplementemia (< 80 mg/dl)  9.47 1.14 to 78.77 0.0375 
Profile anti-PPS < 5 mg at Day 7 and 30 after HTc  14.82 3.44 to 63.77 0.0003 
Profile Day 7 IgG < 600 mg/dl and C3 < 80 mg/dl  12.37 3.38 to 45.28 0.0001 
    
 
C3, complement factor 3; CI, confidence interval; IgG, immunoglobulin G; PPS, polysaccharide antigen. a Cut-off was established 
by receiver-operating characteristic analysis.  
b After adjustment for the following clinical variables: time in intensive care unit > 6 days and participating center.  
c After adjustment for the following clinical variables: time inintensive care unit > 6 days; use of pneumococcal vaccine; and 
participating center. 
We identified 2 humoral immunity profiles that were more strongly associated with the risk of 
bacterial infections: presence of IgG hypogammaglobulinemia and C3 hypocomplementemia at 1 week 
and maintained low anti-polysaccharide response, defined as levels of anti-PPS antibodies < 5 mg/dl at 
Days 7 and 30 (Table 3).  
 
CMV disease was the first infectious complication in 16 patients during the study period. Meantime 
from transplantation to development of CMV disease was 103 days (interval 44 to 180 days) (see Table 
S5 in Supplementary Material online). Independent immunologic risk factors for CMV disease after 
transplantation were IgG hypogammaglobulinemia and lower anti-CMV titers at Day 7, IgG levels < 500 
mg/dl, IgA levels < 80 mg/dl and C3 levels < 80 mg/dl at 1 month. Interestingly, having a lower anti- 
CMV antibody titer was an independent risk factor after adjustment for discordant CMV serostatus as the 
classic risk factor for CMV disease (Table 4).   
Table 4 Multivariate Logistic Regression Analysis of Immunologic Risk Factors for Development of CMV Disease 
Variable  Odds ratiob 95% CI p-value 
    
Day 7 IgG hypogammaglobulinemia (< 600 mg/dl)  6.96 1.34 to 36.04 0.021 
Day 7 anti-CMV titer < 15,000a  8.53 1.57 to 46.22 0.013 
Day 7 C3 hypocomplementemia (< 80 mg/dl)  3.35 0.81 to 13.90 0.095 
Profile Day 7: IgG < 600 mg/dl and C3 < 80 mg/dl  3.73 0.83 to 16.76 0.085 
Day 30 IgG hypogammaglobulinemia (< 500 mg/dla) 8.91 2.15 to 36.84 0.0025 
Day 30 IgA hypogammaglobulinemia (< 80 mg/dla) 17.08 2.84 to 102.61 0.0019 
Day 30 C3 hypocomplementemia (< 80 mg/dla) 13.26 1.93 to 90.88 0.0085 
Discordant CMV serologic status (D+/R−)c  7.03 0.24 to 207.33 0.26 
    
 
CI, confidence interval; CMV, cytomegalovirus; D+, donor positive; R−, recipient negative.  
a Cut-off was established by receiver-operating characteristic analysis.  
b After adjustment for the following clinical variables: discordant CMV serologic status of D and R; methylprednisolone use in 
induction protocol; and participating center.  
c After adjustment for the following variables: IgG Day 7 < 600 mg/dl; methylprednisolone use in induction protocol; and 
participating center. 
Early fatal infections  
Eight patients (4.7%) died of their infections during the first 2 weeks after transplantation. Before 
heart transplantation, these patients had significantly lower levels of C3 (116 ± 13 vs 139 ± 37 mg/dl, p = 
0.006) and of anti-pneumococcal polysaccharide antibody (9 ± 8 vs 29 ± 65 mg/dl, p = 0.004). A trend 
toward lower levels of pre-transplant IgA (203 ± 99 vs 284 ± 137 mg/dl, p = 0.057) and C4 (22 ± 7 vs 26 
± 9 mg/dl, p = 0.16) was also observed. Four of 11 patients (36.4%) who required previous mechanical 
support developed early fatal infections, as compared with only 4 of 159 (2.5%) heart recipients not using 
ventricular assist devices (p < 0.001). Donor age was significantly higher in these patients (52 ± 4 vs 40 ± 
12, p = 0.032). Age > 50 years (p = 0.58), induction therapy (p = 0.45), previous mechanical ventilation 
(p = 0.93), intubation time (p = 0.75), high urgency (p = 0.37), therapy with cephalosporins (p = 0.49) and 
therapy with quinolones (p = 0.25) were not associated with fatal infections.  
Variability of biomarkers between centers  
A total of 122 IgG and 170 C3 determinations were performed at the collaborating centers. Good 
reproducibility was observed for pre- and post-transplant IgG and C3 levels when these values were 
correlated with the values obtained after assessment of the same serum samples at the coordinating center 
(Figure 4).  
  
 
 
 
Figure 4 Evaluation of reproducibility of serum IgG and C3 testing. 
Baseline serum BAFF levels, IgG hypogammaglobulinemia and clinical outcomes  
Median pre-transplant serum BAFF concentration of the entire cohort was 1,366.59 pg/ml (388.6 to 
3,842.10 pg/ml). BAFF levels disclosed a weakly significant correlation with IgG concentration 
(Pearson’s correlation coefficient 0.307; p = 0.002). Median BAFF levels before heart transplantation 
were lower in patients with pre-transplant IgG hypogammaglobulinemia than in patients without IgG 
hypogammaglobulinemia, although the difference was not significant (1,007.7 [453.7 to 2,030.2] vs 
1,415.7 [388.6 to 3,842.1 pg/ml]; p = 0.177). When we stratified the patients according to the median 
value of BAFF, we found no significant correlation with IgG hypogammaglobulinemia at Day 7 (OR = 
0.83, 95% CI 0.31 to 2.24; p = 0.71), IgG hypogammaglobulinemia at Day 30 (OR = 0.86, 95% CI 0.38 
to 1.96; p = 0.71) or development of post-transplant severe infections (OR = 0.53, 95% CI 0.22 to1.26; p 
= 0.15). We also analyzed the relationship between pre- transplant BAFF levels and other clinical 
outcomes. During follow-up, 22% of patients developed acute cellular rejection. Interestingly, higher 
serum BAFF level (> 1,400 pg/ml) was a risk factor for development of acute cellular rejection (OR = 
2.99, 95% CI 1.15 to7.82; p = 0.024) (Figure 5). The OR for acute cellular rejection remained significant 
after adjustment for the variable “participating center” (OR = 3.04, 95% CI 1.15 to 8.06; p = 0.025). 
  
 
 
 
Figure 5 Pre-transplant levels of BAFF were significantly lower in heart recipients developing acute cellular rejection after 
transplantation. Kaplan–Meier curves show the cumulative risk for development of acute cellular rejection during follow-up after 
transplantation according to pre-transplant serum BAFF levels. 
Discussion 
No new predictors of infection in heart recipients have been incorporated into clinical practice in the 
last few years.  
 
Some biomarkers are already considered risk factors for specific severe infections and are being 
included in guidelines, that is, measurement of specific anti-CMV cellular responses for development of 
CMV disease.
9–11
 Further validation of specific biomarkers in large-scale international multicenter studies 
is necessary before they can be accepted as predictors of the risk of infection in clinical practice. 
Unfortunately, no biomarker has been sufficiently validated to be acceptable. We have provided relevant 
information in this regard.  
 
IgG hypogammaglobulinemia has been evaluated extensively as a potential biomarker in specific 
heart transplantation settings.
3–7
 However, IgG levels and other markers of humoral immunity are not 
included in routine protocols. We have presented the results of the first multicenter, prospective, follow-
up study performed in adult heart recipients to assess IgG hypogammaglobulinemia as a predictor of 
severe infections. 
 
We found that, early after transplantation (i.e.,1week), IgG hypogammaglobulinemia is an 
independent risk factor for severe infection in general, bacterial infections in particular, and CMV 
disease. We previously demonstrated that other humoral immunity markers, including C3 
hypocomplementemia, are associated with a high risk of infection.
8,12
 We demonstrated that combined 
assessment of IgG hypogammaglobulinemia and C3 hypocomplementemia at 1 week after transplantation 
is a robust approach for identification of heart recipients at risk of infections. Importantly, we observed 
that serum levels of both components in this simple and easily available humoral immunity profile (IgG 
and C3 levels) correlated well between the coordinating center and the collaborating centers. This finding 
is important when considering the introduction of these biomarkers into clinical practice.  
 
Among the markers tested for identifying the risk of specific infectious complications, the predictive 
value of anti-CMV titers was greater than that obtained with the classic risk factor of donor–recipient 
discordance in CMV serostatus. Low anti-CMV antibody titers were also associated with a high risk of 
CMV infection among CMV recipients with a positive serostatus (data not shown).
13
 A limitation of this 
biomarker is that it is based on an ELISA that used CMV antigensin fibroblasts. It has been suggested 
that the evaluation of humoral anti-CMV responses is better when performed using tests based on 
epithelialcells.
14
 We have previously described the potential role of this biomarker combined with the 
assessment of CD8 cellular responses against the IE-1 antigen of CMV to identify the risk of CMV 
infection.
9
  
 
Low IgG anti-PPS levels at Days 7 and 30 post-transplant identified those individuals who were most 
likely to develop severe bacterial infections. This is a notable finding, given that severe bacterial 
infections are the most frequent infectious complications after heart transplantation.
15
 The Anti-PPS test 
is commonly used as a surrogate of the anti-polysaccharide immune response in patients with recurrent 
infections. Thus, the lower the anti-polysaccharide antibody response, the higher the risk of bacterial 
infections.  A limitation of this evaluation is that it is affected by the type of pneumococcal vaccine used 
in the pre-transplant period. All patients evaluated had received 1 dose of a 23-valent pneumococcal 
polysaccharide vaccine. Updated recommendations include conjugated 13-valent pneumococcal vaccine 
for adult transplant candidates and recipients followed by the polysaccharide vaccine to increase serotype 
coverage.
16
 New ways of evaluating the maintenance of anti- polysaccharide response after 
transplantation should be evaluated.  
 
The Cleveland Clinic Group started the process of evaluating IgG hypogammaglobulinemia as a 
biomarker in heart transplantation. This biomarker has also been evaluated in other types of solid-organ 
transplantation.
17–21
 The results of our national multicenter study add to previous findings from a meta-
analysis on the process of validating this biomarker.  
 
In spite of its low sensitivity, a humoral immunity profile (i.e., IgG < 600 mg/dl + C3 < 80 mg/dl at 
Day 7) may prove to be a reliable marker for monitoring the risk of severe infection in heart recipients, 
owing to its high specificity.  
 
We propose an immunologic score based on humoral immunity parameters that may be useful for 
identifying a subgroup of heart recipients at high risk of severe infections. We previously evaluated the 
role of combined use of humoral and cellular biomarkers in a single-center study.
8
 The potential role of 
adenosine triphosphate (ATP) measurement on CD4
+
 T cells has also been evaluated in a longitudinal 
study. Kobashigawa et al 
22
 observed that ATP levels were significantly lower among patients in whom 
infections were diagnosed within 1 month after evaluation than among those who did not develop 
infection. Because it is unlikely that any single marker predicts everything, future prospective, 
multicenter studies evaluating the combination of humoral immune responses with functional cellular 
responses are anticipated. The cost of measuring the biomarkers should be taken into account. As an 
example, reagents for IgG and C3 levels cost around €5 per test, whereas reagents for the functional 
evaluation of ATP production by CD4 cells cost about €212 per test.  
 
To evaluate potential humoral immunity mechanisms leading to IgG hypogammaglobulinemia, we 
assessed serum BAFF levels in the pre-transplant evaluation. We failed to demonstrate any statistically 
significant association between BAFF levels and IgG hypogammaglobulinemia or severe infection. 
Interestingly, when evaluating the relationship between this biomarker and other clinical outcomes, we 
found an association with acute cellular rejection. The binding of BAFF to the BAFF receptor expressed 
by a subset of CD4+ T cells stimulates T-cell activation and alloproliferation in mice.
23
 An experimental 
model of heart transplantation showed that targeting the BAFF cytokine network inhibits both humoral 
and cellular immune responses induced by memory CD4 T cells.
24
 For the first time, we suggest the 
potential role of serum BAFF as a pre-transplant biomarker of acute cellular rejection in heart recipients. 
Limitations 
A limitation of our study is the inclusion of centers with a small number of patients. The Cis of some 
biomarkers were wide, indicating that the overall sample size was small. Binary cut-offs could not yield 
homogeneous populations that may continue to be present in larger samples, although the 95% CI swould 
be narrower. Some of the variables used probably have more than 2 risk populations, and reducing to 2 
populations produces larger 95% CIs. We identified several clinical risk factors of infection; however, 
other major clinical risk factors for infection may not have been identified owing to the low statistical 
power. Nevertheless, in this proof-of-concept study, some variables were clearly associated with the 
incidence of infection, and the metrics of these variables could be analyzed in further studies to establish 
more accurate boundaries. The logical next step is an international multicenter study in this field with a 
larger number of patients. 
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